Thyroid carcinoma
|
0.590 |
Biomarker
|
disease |
BEFREE |
Some somatic oncogene mutations (BRAF, NRAS, HRAS, KRAS) as well as gene translocations (RET/PTC, PAX8/PPAR-gamma) have been associated with the development of thyroid cancer.
|
26259532 |
2016 |
Thyroid carcinoma
|
0.590 |
GeneticVariation
|
disease |
BEFREE |
Diagnostically, KRAS mutation testing is useful in the workup of pancreaticobiliary and thyroid cancers, particularly using cytological specimens.
|
25487540 |
2015 |
Thyroid carcinoma
|
0.590 |
Biomarker
|
disease |
BEFREE |
Mutations in BRAF, NRAS, KRAS and PTEN, that are known to be involved in thyroid cancer biology, were detected in seven FNA samples.
|
24834793 |
2015 |
Thyroid carcinoma
|
0.590 |
GeneticVariation
|
disease |
BEFREE |
KRAS(S65N) was identified for the first time in thyroid cancer and could activate mitogen-associated protein kinase (MAPK).
|
24798740 |
2014 |
Thyroid carcinoma
|
0.590 |
GeneticVariation
|
disease |
BEFREE |
Despite KRAS being the 6th most frequently mutated gene for all cancers, the reported frequency in thyroid cancer is only 2%.
|
22930660 |
2014 |
Thyroid carcinoma
|
0.590 |
GeneticVariation
|
disease |
BEFREE |
Fourteen FNMTCs in patients from seven families were analyzed in terms of involvement of the four susceptibility loci, and 63 thyroid cancer tumors [FNMTC (29) and NMTC (34)] were evaluated for the occurrence of mutations in BRAF, and H-, N-, and K-RAS, using polymerase chain reaction, single-strand conformation polymorphism (PCR-SSCP) analysis, and direct sequencing.
|
21826673 |
2012 |
Thyroid carcinoma
|
0.590 |
GeneticVariation
|
disease |
BEFREE |
The effect of activating somatic mutations in the KRAS and BRAF genes on the responsiveness to sunitinib was evaluated in a panel of thyroid cancer cell lines harboring wild-type KRAS and BRAF genes, the RET/PTC1 rearrangement, the G12R KRAS, or the V600E BRAF mutation.
|
22442268 |
2012 |
Thyroid carcinoma
|
0.590 |
GeneticVariation
|
disease |
BEFREE |
We examined the activity of PLX4032 and PLX4720 in thyroid carcinoma cell lines harboring BRAF V600E (8505C, BCPAP, SW1736, BHT101), NRAS Q61R (HTH7), KRAS G12R (CAL62), HRAS G13R (C643), or RET/PTC1 (TPC-1) oncogenes.
|
19880792 |
2010 |
Thyroid carcinoma
|
0.590 |
Biomarker
|
disease |
BEFREE |
We conclude that wild-type K-Ras.GTP in association with Gal-3 contributes to thyroid carcinoma malignancy and that Ras inhibition might be a useful treatment strategy against these deadly tumors.
|
20682656 |
2010 |
Thyroid carcinoma
|
0.590 |
Biomarker
|
disease |
CTD_human |
Agent-specific ras oncogene activation in rat thyroid tumours.
|
3078959 |
1988 |
Thyroid carcinoma
|
0.590 |
CausalMutation
|
disease |
CGI |
|
|
|